Athira Pharma, Inc.·Healthcare

HIGHLIGHTS Ongoing site mobilization commenced in mid-March - including fuel, supplies, & equipment inclusive of delivery of a third diamond drill, supplied by Base Diamond Drilling Ltd. - in support of the 2026 Exploration Program at the Angilak Uranium Project; Mobilization is being completed via ATR planes (Photo 1 & 2) departing from Yellowknife, Northwest Territories, and Baker Lake and Rankin Inlet, Nunavut, and landing on Angilak's Winter landing strip; The 2026 Angilak Exploration Program, and beyond, is fully funded with the February closing of CAD $63 Million financing, making ATHA one of the best capitalized uranium exploration Companies globally; 2026 Angilak Exploration Program will be the largest to date on the project, following up on the highly successful 2024 & 2025 campaigns: 2024 maiden campaign focused on expansion of the mineralizing footprint along the Lac 50 Deposit Corridor, culminating in the release of 2024 Exploration Target3; 2025 Program focused on testing the regional prospectivity within the Angikuni Basin along the Mineralized RIB & KU-Nine Iron Corridors, outside of the Lac 50 Deposit area, resulting in the discovery of five new uranium showings - including RIB North, where the maiden hole intersected 34.7 m of composite uranium mineralization1 with grades up to 8.16% U3O8 over 0.5 m; The Company anticipates exploration activities, including diamond drilling, to commence by the latter part of April.

Tightening share structure ahead of fully-funded, maiden drill program in Red Lake WHITE ROCK, BC / ACCESS Newswire / March 27, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") announces that its Board of Directors has approved a consolidation of the Company's issued and outstanding common shares on the basis of every nine point nine (9.9) pre-consolidation common shares for every one (1) post-consolidation common share (the "Consolidation"). Pursuant to the Business Corporations Act (British Columbia) and the Company's articles the Board of Directors is authorized to approve certain changes to the Company's capital structure, including the Consolidation, as such, shareholder approval is not required.

InflaRx (NASDAQ: IFRX - Get Free Report) and Athira Pharma (NASDAQ: ATHA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Risk and Volatility InflaRx has a beta of

Drilling returns 1.25 g/t Au over 33.54m; Buster Trend further expanded WHITE ROCK, BC / ACCESS Newswire / March 19, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project in Nevada. Mammoth Minerals Limited (ASX: M79) (formerly Firetail Resources Limited) has been aggressively exploring Excelsior, per its option agreement to earn an 80% interest in the project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see press releases dated June 2, 2025, and August 22, 2025).

WHITE ROCK, BC / ACCESS Newswire / March 13, 2026 / Athena Gold Corporation (CSE:ATHA) (OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce that, further to its press release dated February 26, 2026, it has completed the acquisition of the Forester Gold Project ("Forester" or the "Project") through the acquisition of Last Bounty Gold Corp. ("Last Bounty"), a private British Columbia company that holds a 100% interest in the Project, pursuant to a share purchase agreement dated February 25, 2026. "We are thrilled to close the Forester acquisition, a pivotal step in refocusing Athena as a disciplined explorer of high-potential, historically overlooked ground near multimillion-ounce gold producers.

All-share deal to acquire a 100% interest in Forester WHITE ROCK, BC / ACCESS Newswire / February 26, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce the proposed acquisition of a 100% interest in the Forester Gold Project ("Forester" or the "Project"), located along-trend of Orla Mining's Musselwhite Gold Mine in northwestern Ontario. Highlights 100% ownership of the 4,900-hectare Forester Gold Project, to be acquired via a low-cost, all-share deal with no known encumbrances other than the existing 2% net smelter return ("NSR") royalty, half of which is repurchaseable for $2 million, adjusted for inflation.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.